Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QVV0
Wed, 26.03.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Ladenburg, Germany, 26 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting its latest ADC research results and [ … ]
Fri, 21.03.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
Promising data from clinical trial with HDP-101 in multiple myeloma, including a complete remission in one female patient; study is making good progress
Received first approvals for the clinical study with ATAC candidate HDP-102; st [ … ]
Thu, 13.03.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
HealthCare Royalty and Heidelberg Pharma amend royalty financing agreement to provide for USD 20 million payment
Heidelberg Pharma extends cash runway into 2027
Ladenburg, Germany, 13 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company [ … ]
Mon, 13.01.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
HDP-101 is well tolerated to date, with no signs of dose-limiting toxicities
Complete remission observed in one patient from Cohort 5
Proprietary novel payload with a unique mode of action, representing new [ … ]